$AZN
Market Cap:
$AZN SEC Filings
| Filing | Filed On |
|---|---|
| CALQUENCE RECOMMENDED FOR EU APPROVAL IN 1L MCL | 31 Mar 2025 |
| IMFINZI APPROVED IN THE US FOR BLADDER CANCER | 31 Mar 2025 |
| AZN INVESTS $2.5BN IN BEIJING R&D & MANUFACTURING | 21 Mar 2025 |
| IMFINZI APPROVED IN EU FOR LIMITED-STAGE SCLC | 17 Mar 2025 |
| ASTRAZENECA TO ACQUIRE ESOBIOTEC | 17 Mar 2025 |
| ENEBOPARATIDE PHASE III TRIAL MET PRIMARY ENDPOINT | 17 Mar 2025 |
| HOLDING(S) IN COMPANY | 12 Mar 2025 |
| NOTICE OF AGM | 07 Mar 2025 |
| FORM 6-K | 07 Mar 2025 |
| DIRECTOR/PDMR SHAREHOLDING | 07 Mar 2025 |
| IMFINZI IMPROVED EFS IN EARLY-STAGE GASTRIC CANCER | 07 Mar 2025 |
| DIRECTOR/PDMR SHAREHOLDING | 06 Mar 2025 |
| DIRECTOR/PDMR SHAREHOLDING | 05 Mar 2025 |
| TOTAL VOTING RIGHTS | 03 Mar 2025 |
| IMFINZI RECOMMENDED FOR EU APPROVAL FOR AEGEAN | 03 Mar 2025 |
| ENHERTU RECOMMENDED IN EU IN POST-ET BREAST CANCER | 28 Feb 2025 |
| CAMIZESTRANT IMPROVED PFS IN 1L HR+ BREAST CANCER | 26 Feb 2025 |
| FILING OF FORM 20-F WITH SEC | 19 Feb 2025 |
| HOLDING(S) IN COMPANY | 18 Feb 2025 |
| FORM 6-K | 18 Feb 2025 |
